BR112015006282B1 - Composições e usos de capromorelina para controle de inapetência - Google Patents

Composições e usos de capromorelina para controle de inapetência Download PDF

Info

Publication number
BR112015006282B1
BR112015006282B1 BR112015006282-2A BR112015006282A BR112015006282B1 BR 112015006282 B1 BR112015006282 B1 BR 112015006282B1 BR 112015006282 A BR112015006282 A BR 112015006282A BR 112015006282 B1 BR112015006282 B1 BR 112015006282B1
Authority
BR
Brazil
Prior art keywords
capromorelin
composition
animals
day
serum
Prior art date
Application number
BR112015006282-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015006282A2 (pt
Inventor
Bill ZOLLERS
Linda RHODES
Ernst Heinen
Gopinath DEVARAJ
Original Assignee
Aratana Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics, Inc filed Critical Aratana Therapeutics, Inc
Publication of BR112015006282A2 publication Critical patent/BR112015006282A2/pt
Publication of BR112015006282B1 publication Critical patent/BR112015006282B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Dermatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112015006282-2A 2012-09-27 2013-09-27 Composições e usos de capromorelina para controle de inapetência BR112015006282B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706164P 2012-09-27 2012-09-27
US61/706,164 2012-09-27
PCT/US2013/062227 WO2014052780A2 (en) 2012-09-27 2013-09-27 Compositions and methods of use of an inappetance-controlling compound

Publications (2)

Publication Number Publication Date
BR112015006282A2 BR112015006282A2 (pt) 2017-07-04
BR112015006282B1 true BR112015006282B1 (pt) 2021-11-23

Family

ID=50339468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006282-2A BR112015006282B1 (pt) 2012-09-27 2013-09-27 Composições e usos de capromorelina para controle de inapetência

Country Status (18)

Country Link
US (1) US11090292B2 (https=)
EP (3) EP3524260B1 (https=)
JP (2) JP6779618B2 (https=)
KR (6) KR20250048114A (https=)
CN (2) CN111419845A (https=)
AR (2) AR092713A1 (https=)
AU (2) AU2013323349B2 (https=)
BR (1) BR112015006282B1 (https=)
CA (1) CA2886091C (https=)
DK (1) DK3524260T3 (https=)
ES (1) ES2959427T3 (https=)
MX (2) MX2015003564A (https=)
NZ (2) NZ746394A (https=)
PL (1) PL3524260T3 (https=)
PT (1) PT3524260T (https=)
RU (1) RU2648958C2 (https=)
TW (3) TWI732158B (https=)
WO (1) WO2014052780A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975070B2 (en) 2010-02-26 2021-04-13 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
BR112015006282B1 (pt) 2012-09-27 2021-11-23 Aratana Therapeutics, Inc Composições e usos de capromorelina para controle de inapetência
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US9700591B2 (en) * 2015-01-28 2017-07-11 Aratana Therapeutics, Inc. Compositions and methods for chronic use of a weight-gaining compound
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2018089723A1 (en) * 2016-11-11 2018-05-17 Hill's Pet Nutrition, Inc. Compositions and methods of pet food

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US193273A (en) * 1877-07-17 Improvement in material for pulley-covers
JP2893901B2 (ja) * 1990-09-07 1999-05-24 株式会社岐阜免疫研究所 動物用抗体含有油性ペースト製剤
CA2095786A1 (en) * 1992-05-08 1993-11-09 Franco J. Vaccarino Method of stimulating appetite
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
US8226973B2 (en) * 2005-11-02 2012-07-24 Nestec, S. A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
NZ571183A (en) * 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US8299022B2 (en) 2006-09-27 2012-10-30 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the N-terminal
JP2008127377A (ja) * 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US20080226802A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Beverage having natural sweeteners with one or more stevia components and source of berry
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
RU2007129408A (ru) * 2007-07-31 2009-02-10 Игорь Николаевич Жирков (RU) Способ выращивания поросят в период откорма
FR2920295B1 (fr) 2007-09-05 2009-12-11 Desvac Dispositif d'injection de produits veterinaires a des volailles, comprenant un element de contention presentant une forme anatomique incluant des moyens de calage d'un os reperable
CN101854814B (zh) * 2007-11-12 2013-07-31 三荣源有限公司 改善甜叶菊提取物甜味的方法
EP2412713B1 (en) * 2009-03-26 2016-11-30 Takeda Pharmaceutical Company Limited Pyrazole compound
US10975070B2 (en) 2010-02-26 2021-04-13 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
BR112015006282B1 (pt) 2012-09-27 2021-11-23 Aratana Therapeutics, Inc Composições e usos de capromorelina para controle de inapetência

Also Published As

Publication number Publication date
NZ746394A (en) 2019-01-25
EP2906041A2 (en) 2015-08-19
KR20220003640A (ko) 2022-01-10
JP6796097B2 (ja) 2020-12-02
KR20250048114A (ko) 2025-04-07
WO2014052780A3 (en) 2014-06-26
KR20230097201A (ko) 2023-06-30
US20140088139A1 (en) 2014-03-27
CN105072909A (zh) 2015-11-18
JP6779618B2 (ja) 2020-11-04
AR123902A2 (es) 2023-01-25
PL3524260T3 (pl) 2023-11-27
MX2015003564A (es) 2015-11-16
CA2886091C (en) 2021-11-30
JP2016500660A (ja) 2016-01-14
AU2013323349B2 (en) 2016-09-15
BR112015006282A2 (pt) 2017-07-04
CN111419845A (zh) 2020-07-17
AU2016216741B2 (en) 2018-02-15
AU2016216741A1 (en) 2016-09-15
TW201417812A (zh) 2014-05-16
TWI732158B (zh) 2021-07-01
EP4302825A3 (en) 2024-07-03
AU2013323349A1 (en) 2015-05-07
ES2959427T3 (es) 2024-02-26
EP3524260B1 (en) 2023-09-13
US11090292B2 (en) 2021-08-17
EP2906041A4 (en) 2016-10-26
RU2648958C2 (ru) 2018-03-28
KR20150058345A (ko) 2015-05-28
WO2014052780A2 (en) 2014-04-03
JP2018117625A (ja) 2018-08-02
TWI667024B (zh) 2019-08-01
MX2022015141A (es) 2023-02-01
AR092713A1 (es) 2015-04-29
CA2886091A1 (en) 2014-04-03
KR20210009438A (ko) 2021-01-26
EP4302825A2 (en) 2024-01-10
NZ707174A (en) 2018-10-26
RU2015114996A (ru) 2016-11-20
DK3524260T3 (da) 2023-10-09
KR20190143484A (ko) 2019-12-30
TW201924680A (zh) 2019-07-01
TW202106298A (zh) 2021-02-16
EP3524260A1 (en) 2019-08-14
PT3524260T (pt) 2023-10-13

Similar Documents

Publication Publication Date Title
JP6796097B2 (ja) 食欲不振制御化合物の組成物および使用方法
JP7120718B2 (ja) 体重増加用化合物の長期使用のための組成物と方法
HK40104431A (en) Pharmaceutical compositions for treatment of inappetence

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/58 , A01N 43/60

Ipc: A61K 31/437 (2006.01), A61P 1/14 (2006.01)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2013, OBSERVADAS AS CONDICOES LEGAIS.